Related Experiment Video
Updated: May 31, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Huntington's disease: effect of memantine on FDG-PET brain metabolism?
Lena Elisabeth Hjermind1, Ian Law, Aia Jønch
1Neurogenetics Clinic, Memory Disorders Research Group, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. jermind@sund.ku.dk
Abstract:
In this open-label pilot study, the authors evaluated the effect of memantine on the distribution of brain glucose metabolism in four Huntington's disease (HD) patients as determined by serial 18-fluoro-deoxyglucose [F(18)]FDG-PET scans over a period of 3-4 months (90-129 days, with one patient choosing to continue treatment over the 18-month follow-up period). The treatment regimen was well tolerated. No significant differences on neuropsychological parameters before and after treatment were detected; but the patient who continued treatment did not deteriorate at 18 months' reevaluation, whereas the three patients who had stopped treatment after 3 to 4 months had minor progression in all cognitive domains on re-evaluation 12 months after the end of treatment.
Related Concept Videos
Alzheimer's Disease: Treatment
Huntington Disease l: Introduction
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
